Navigation Links
Pagoclone in Medical News

Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. About SANCTURA and SANCTURA XR SANCTURA(R) and SANCTURA XR(TM) belong to a class of anticholinergic compounds known as mus...

Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. About Endo Pharmaceuticals Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, ...

Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. About Endo Pharmaceuticals Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development...

Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. About Orion Corporation ( http://www.orion.fi ) Orion is a European pharmaceutical and diagnostics company which emphasises the de...

Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Pharmaceuticals To Present at RBC Capital Markets Conference

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Pharmaceuticals to Present at Upcoming Investor Conferences

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

With an aim to cure stuttering

...ng to the company. However, even larger trials were needed. According to New York Times, larger trials could take 2-3 years but if they succeed, pagoclone would become the first medicine for treating the problem. Research is concentrating on the idea that stammering is a neurological problem, which...
Pagoclone in Medical Technology

Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering

LEXINGTON, Mass., Sept. 26 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that it has signed a development, license and commercialization agreement with Teva Pharmaceutical Industries Ltd. for the exclusive, worldwide rights to pagoclone. Indevus previously anno...

Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting

Open-label Extension of Phase II Study Demonstrates Significant Additional Improvement for Patients on Pagoclone LEXINGTON, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced that results from the Company's Phase II EXPRESS trial for pagoclone in persisten...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Secur...

Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. PRO 2000 PRO 2000 (a naphthalene sulfonate polymer) is under development as a topical vaginal microbicide to prevent the s...

Indevus Pharmaceuticals Provides Update on PRO 2000 Program

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. PRO 2000 PRO 2000 (naphthalene sulfonate polymer) is a topical vaginal microbicide under development to prevent the sexual transmi...

Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Announces Submission of New Drug Application

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Reports Positive Data From Phase III NEBIDO Trial

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...
Pagoclone in Biological Technology

Indevus Pharmaceuticals Announces Release of 2008 Annual Report

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Contact: Michael W. Rogers EVP and Chief Financial Officer (781) 861-8444 Robin L. DeCarlo Sr. Directo...

Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results

...late stage development programs for octreotide and pagoclone are in full gear, and our successful $105 million ...ent with Teva for the development and marketing of pagoclone for the treatment of stuttering. In the first cal... Allergan -- Licensing of Worldwide Rights for pagoclone to Teva Corporate -- Issuance of U.S. Pa...

Indevus Pharmaceuticals to Present at Upcoming Investor Conferences

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. About the Jericho Road Episcopal Housing Initiative The Jericho Road Episcopal Housing Initiative creates quality homes for famili...

Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Announces Allergan as New Partner for SANCTURA Brand

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. About SANCTURA and SANCTURA XR SANCTURA(R) and SANCTURA(R) XR belong to a class of anticholinergic compounds known as muscarinic rec...

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...
Other Tags
(Date:9/19/2014)... (PRWEB) September 19, 2014 Boston Scientific ... mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled ... month, Bernstein Liebhard LLP reports. According to ... Court, the company asserts that claims involving its Solyx ... Practice and Remedies Code, a section of which shields ...
(Date:9/19/2014)... brain structure could help predict how willing you are to ... Yale University found those with greater volume in a part ... more likely to engage in risky behavior than people with ... by the U.S. National Institute on Aging, involved two groups ... The researchers sought to determine how brain structure influences risk ...
(Date:9/19/2014)... News) -- Although there is mounting evidence that ... and older adults in the United States don,t ... new research. Less than one-quarter of adults ... the Department of Health and Human Services, the ... promoting health and fitness and staying independent, researchers ...
(Date:9/19/2014)... Alan Mozes HealthDay Reporter ... Cancer patients burdened by stress and family conflicts before ... their operation, a new study suggests. Investigators found ... have a nearly three times greater risk for complications ... of life. "We,ve long known that patient quality ...
(Date:9/19/2014)... 2014 Lipitor lawsuits ( http://www.thelipitorlawsuit.com/ ... to develop Type 2 diabetes continue to move forward ... District Court, District of South Carolina, Bernstein Liebhard LLP ... 12, 2014, discovery is underway and moving forward in ... Pfizer, Inc., the manufacturer of Lipitor, has produced millions ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3
(Date:9/19/2014)... a species which over thousands of years has adapted to ... substance that makes the cold dangerous for you. , This ... , and the cold provoking substance, called nonylphenol, comes from ... is suspected of being a endocrine disruptor, but when entering ... worm,s ability to protect the cells in its body from ...
(Date:9/19/2014)... legume plants regulate their symbiotic relationship with soil ... through the plant structure from leaves into the ... in the roots. This collaborative study was conducted ... Biology, the Graduate University for Advanced Studies (SOKENDAI), ... in Japan. , Legumes, an important plant ...
(Date:9/18/2014)... Bulletin study uses tree rings to document arroyo ... in northern New Mexico, USA. By determining burial dates ... were able to precisely date arroyo sedimentary beds 30 ... with aerial imagery, LiDAR, longitudinal profiles, and repeat surveys ... are deep, oversized channels that have vertical or steeply ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3For legume plants, a new route from shoot to root 2Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
Other Contents